期刊文献+

临床药师对晚期肺腺癌序贯药学实践体会 被引量:2

下载PDF
导出
摘要 目的:通过临床药师参与晚期肺癌1例患者的药物治疗实践,保障该患者的用药安全有效。方法:行吉西他滨+顺铂方案化疗,4疗程后停药2个月查胸部CT病灶有进展;改吉非替尼服用1个月,复查CT病灶有进展;改用厄罗替尼治疗1个月复查病情仍进展;改培美曲塞+顺铂化疗2次,CT示病灶缩小,但骨髓抑制明显;改单药培美曲塞化疗2次,CT示右侧胸腔及心包积液较前增多;后用多西他赛化疗7次,病灶仍进展,后又用吉西他滨+顺铂方案2个疗程因不能耐受,改单药使用2个疗程。结果:避免了潜在的医疗风险,提高了患者用药依从性。结论:临床药师参与晚期肺腺癌序贯药物治疗,有利于提高临床药物治疗水平。
出处 《交通医学》 2012年第2期168-170,共3页 Medical Journal of Communications
  • 相关文献

参考文献6

二级参考文献24

共引文献70

同被引文献21

  • 1Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in pre- viously treated non-small-cell lung cancer [ J ]. N Engl J Med, 2005, 353(2) :123.
  • 2Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR21 [J]. J Clin Oncol,2006,24(24) :3831.
  • 3Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adeno- carcinomas to gefitinib or erlotinib is associated with a second muta- tion in the EGFR kinase domain[ J]. PLoS Med,2005,2 (3) :225.
  • 4Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 sig- naling[ J ]. Science ,2007,316 ( 5827 ) : 1039.
  • 5Herbst RS,Johnson DH,Mininberg E,et al. Phase trial evalua-ting the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-I/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer[ J ]. J Clini Onco1,2005,23 ( 11 ) :2544.
  • 6Uramoto H, Iwata T, Onitsuka T, et al. Epithelial -mesenchymal tran- sition in E GFR-TKI acquired resistant lung adenocarcinoma[ J ]. Anti- cancer Res,2010,30(7) :2513.
  • 7Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor:A random- ized, double-blind phase Ill trial (ZEPHYR) [ J ]. J Clin Oncol,2012, 30(10) :1114.
  • 8Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarci- noma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three eases [ J ]. Oncol Res, 2005,15 (2) :107.
  • 9Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regi- mens : E2501 [ J ]. J Clin Onco1,2008,26 ( suppl 15 ) : 8014.
  • 10徐文静,黄纯,李凯.厄洛替尼治疗晚期肺癌10例疗效观察[J].天津医药,2009,37(1):65-66. 被引量:3

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部